Cudraxanthone B exhibits significant biological activity, making it valuable in pharmaceutical and biomedical research. It has demonstrated potent anti-inflammatory effects by inhibiting key pro-inflammatory mediators such as nitric oxide and cytokines in cellular models. This property suggests potential use in developing treatments for chronic inflammatory diseases.

Additionally, Cudraxanthone B shows promising anticancer activity. Studies indicate it can suppress the growth of certain cancer cell lines by inducing apoptosis and inhibiting cell proliferation pathways. Its ability to target specific signaling mechanisms in tumor cells highlights its potential as a lead compound in oncology drug development.

The compound also possesses antimicrobial properties, effective against a range of pathogenic bacteria and fungi. This broad-spectrum activity supports its exploration as a new antimicrobial agent, especially in the face of increasing antibiotic resistance.

Due to its antioxidant capacity, Cudraxanthone B may also be useful in protecting cells from oxidative stress, which is linked to aging and several degenerative diseases. Research is ongoing to evaluate its efficacy in neuroprotective applications and metabolic disorders.